Nexentis Technologies (NXTS) EBT (2019 - 2026)
Nexentis Technologies (NXTS) posted EBT of -$11.2 million for Q2 2026, down 2136.98% on a QoQ basis from $549000.0 in Q4 2025, and down 154.91% year-over-year from $20.4 million in Q2 2025.
Analysis
Nexentis Technologies (NXTS) EBT (2019 - 2026) Analysis & Trends
Nexentis Technologies has reported EBT for 8 years, with the latest figure at -$11.2 million in Q2 2026.
- On a quarterly basis, EBT fell 154.91% year-over-year to -$11.2 million in Q2 2026; TTM through Jun 2026 was -$16.3 million, a 145.41% decrease from a year earlier, with the FY2025 full-year figure at -$3.6 million, up 16.35% from the prior year.
- EBT was -$11.2 million for Q2 2026 at Nexentis Technologies, down from $549000.0 in the prior quarter.
- The five-year high for EBT was $549000.0 in Q4 2025, with the low at -$11.2 million in Q2 2026.
- Average EBT over 5 years is -$2.0 million, with a median of -$1.3 million recorded in 2022.
- The sharpest annual moves came in 2022 and 2025: EBT slumped 445.07% in 2022, then jumped 350.68% in 2025.
- Over 5 years, EBT stood at -$1.4 million in 2022, then sank by 49.53% to -$2.1 million in 2023, then surged by 89.75% to -$219000.0 in 2024, then surged by 350.68% to $549000.0 in 2025, then plunged by 2136.98% to -$11.2 million in 2026.
- The last three EBT figures came in at -$11.2 million (Q2 2026), $549000.0 (Q4 2025), and -$1.3 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 2.77 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -10.25 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 1.39 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 1.53 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 542.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -767.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 177.81 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 132.40 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -294.56 Mn |
| 10 | Nexentis Technologies | 1.40 Mn | -7.48 Mn | - | -11.18 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -11.18 Mn |
| Dec 31, 2025 | 549,000.00 |
| Sep 30, 2025 | -1.33 Mn |
| Jun 30, 2025 | -4.39 Mn |
| Mar 31, 2025 | -619,000.00 |
| Dec 31, 2024 | -219,000.00 |
| Sep 30, 2024 | -1.44 Mn |
| Jun 30, 2024 | -847,000.00 |
| Mar 31, 2024 | -911,171.00 |
| Dec 31, 2023 | -2.14 Mn |
| Sep 30, 2023 | -2.86 Mn |
| Jun 30, 2023 | -840,318.00 |
| Mar 31, 2023 | -1.74 Mn |
| Dec 31, 2022 | -1.43 Mn |
| Sep 30, 2022 | -1.77 Mn |
| Jun 30, 2022 | -1.28 Mn |
| Mar 31, 2022 | -1.35 Mn |
| Dec 31, 2021 | -1.57 Mn |
| Sep 30, 2021 | -1.29 Mn |
| Jun 30, 2021 | -1.62 Mn |